Genomic Health Inc., Redwood City, California, United States of America.
PLoS One. 2014 Apr 11;9(4):e94202. doi: 10.1371/journal.pone.0094202. eCollection 2014.
The identification of gene fusions promises to play an important role in personalized cancer treatment decisions. Many rare gene fusion events have been identified in fresh frozen solid tumors from common cancers employing next-generation sequencing technology. However the ability to detect transcripts from gene fusions in RNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissues, which exist in very large sample repositories for which disease outcome is known, is still limited due to the low complexity of FFPE libraries and the lack of appropriate bioinformatics methods. We sought to develop a bioinformatics method, named gFuse, to detect fusion transcripts in FFPE tumor tissues. An integrated, cohort based strategy has been used in gFuse to examine single-end 50 base pair (bp) reads generated from FFPE RNA-Sequencing (RNA-Seq) datasets employing two breast cancer cohorts of 136 and 76 patients. In total, 118 fusion events were detected transcriptome-wide at base-pair resolution across the 212 samples. We selected 77 candidate fusions based on their biological relevance to cancer and supported 61% of these using TaqMan assays. Direct sequencing of 19 of the fusion sequences identified by TaqMan confirmed them. Three unique fused gene pairs were recurrent across the 212 patients with 6, 3, 2 individuals harboring these fusions respectively. We show here that a high frequency of fusion transcripts detected at the whole transcriptome level correlates with poor outcome (P<0.0005) in human breast cancer patients. This study demonstrates the ability to detect fusion transcripts as biomarkers from archival FFPE tissues, and the potential prognostic value of the fusion transcripts detected.
基因融合的鉴定有望在癌症的个体化治疗决策中发挥重要作用。采用下一代测序技术,在常见癌症的新鲜冷冻实体肿瘤中已经鉴定出许多罕见的基因融合事件。然而,由于 FFPE 文库的复杂性低,以及缺乏适当的生物信息学方法,从福尔马林固定石蜡包埋(FFPE)肿瘤组织中分离的 RNA 中检测基因融合转录本的能力仍然有限,这些 FFPE 肿瘤组织存在于具有已知疾病结局的大型样本库中。我们试图开发一种名为 gFuse 的生物信息学方法来检测 FFPE 肿瘤组织中的融合转录本。gFuse 采用基于队列的综合策略,检查来自两个乳腺癌队列(共 136 名和 76 名患者)的 50 个碱基对(bp)单端 FFPE RNA-Seq(RNA-Seq)数据集的单端 50 个碱基对(bp)读长。总共在 212 个样本中以碱基分辨率检测到 118 个融合事件。我们根据其与癌症的生物学相关性选择了 77 个候选融合,并使用 TaqMan 测定法支持了其中的 61%。通过 TaqMan 鉴定的 19 个融合序列的直接测序证实了它们的存在。在 212 名患者中,有 3 对独特的融合基因对反复出现,分别有 6、3、2 个人携带这些融合。我们在这里表明,在整个转录组水平检测到的融合转录本的高频率与人类乳腺癌患者的不良预后(P<0.0005)相关。这项研究证明了从存档的 FFPE 组织中检测融合转录本作为生物标志物的能力,以及检测到的融合转录本的潜在预后价值。